Background Peginterferon a-2a (40 kDa), a new treatment for chronic hepatitis B, produces seroconversion within 48 weeks in approximately 32% of HBeAg-positive patients. Over a defined treatment duration it offers improved efficacy over lamivudine, but at higher cost. We assessed the clinical outcomes and costs, from the perspective of the UK National Health Service, of 48 weeks of peginterferon a-2a (40 kDa) vs. 4 years of lamivudine.
Introduction
An estimated 350 million individuals have chronic hepatitis B (CHB) infection [1, 2] . Estimates by the UK Department of Health suggest that 0.3% (approximately 180 000 cases) of the UK population is infected with CHB [3] . A recent study suggests that a total of 7700 new cases of CHB will be seen each year in the UK with the majority of cases due to migration of individuals into the UK who are infected with HBV [4] . Chronic HBV infection without advanced fibrosis is asymptomatic, but among patients with active viral replication, cirrhosis develops in 15-20% of patients within 5 years [5] . CHB also can lead to hepatocellular carcinoma (HCC) and up to 80% of liver cancer cases worldwide can be attributed to HBV [6] .
In most industrialized regions, the main route of infection is through sexual contact or needle sharing between intravenous drug users. Although safe and effective vaccines for HBV have been available since 1982, universal vaccination has not begun in the UK [7] . For those who develop CHB, treatment with antiviral or interferon-based products is the only clinical treatment option.
In the UK, non-pegylated interferon therapy (IFN-a), lamivudine and adefovir are approved treatments for patients with HBeAg-positive and HBeAg-negative CHB. In HBeAg-positive CHB, IFN-a results in HBeAg seroconversion rates of 30-40% at the end of 4-6 months of therapy and durability of response of 80% 24 weeks 0954-691X c 2007 Lippincott Williams & Wilkins after treatment [8, 9] . The main advantage of IFN-a is that sustained off-therapy response can be achieved with a finite treatment duration. However, IFN-a is associated with dose-limiting adverse events such as flu-like symptoms and depression, and the daily or three times weekly dosing by injection may be inconvenient for patients.
Lamivudine is an oral, nucleoside analogue with activity against HIV and HBV. Unlike IFN-a, it is also approved in CHB patients with decompensated cirrhosis and is the current standard of care for treatment of CHB in the UK. Lamivudine is, however, associated with lower end-oftreatment HBeAg seroconversion rates of 17-21% with 12 months of therapy. Prolonged treatment duration has been shown to increase the response rate; however, once patients stop treatment a high relapse rate is seen (after treatment durability of 30-80%) [8, 9] . Another challenge with lamivudine is the emergence of tyrosine-methionineaspartate-aspartate (YMDD) mutations, which lead to drug resistance. The incidence of lamivudine resistance in HBeAg-positive patients is approximately 26% in year 1 and increases up to 71% at 4 years [10] . This lowers the likelihood that these patients achieve a durable response [11] .
In the UK, adefovir, an oral nucleotide analogue, is approved for treatment in patients with HBeAg-positive and HBeAg-negative CHB and in patients with lamivudine-resistant YMDD mutations. Recent National Institute of Clinical Effectiveness (NICE) guidelines recommend use of adefovir as salvage therapy in lamivudine resistant patients [12] . A major advantage of adefovir over lamivudine is the low incidence of adefovirresistance mutations (15-20% after 4 years of therapy) [13] . However, the HBeAg seroconversion rate with adefovir monotherapy in patients with HBeAg-positive disease is only 12% [8] .
Recently, peginterferon a-2a (40 kDa) was approved in the UK for the treatment of both HBeAg-positive and HBeAg-negative CHB in patients with or without compensated cirrhosis, patients with compensated liver disease and evidence of viral replication and liver inflammation. The approval in HBeAg-positive CHB was based on a recent multicenter randomized clinical trial (N = 542) comparing peginterferon a-2a (40 kDa) for 48 weeks vs. lamivudine for 48 weeks [14] . The primary study end points were the proportion of patients with HBeAg seroconversion and the proportion with HBV DNA viral load < 100 000 copies/ml 6 months after treatment. The study demonstrated that 48 weeks of peginterferon a-2a (40 kDa) monotherapy resulted in significantly higher HBeAg seroconversion at the end of follow-up (week 72) than 48 weeks of lamivudine in patients with HBeAg-positive CHB (32 vs. 19%, P < 0.001).
Using efficacy data from this comparative study, we sought to assess the net health consequences, costs, and cost-effectiveness of peginterferon a-2a (40 kDa) for treatment of patients with HBeAg-positive CHB, compared with lamivudine treatment from the UK National Health Service perspective.
Methods

Analytic overview
A Markov model was used to simulate progression of CHB in a hypothetical cohort of 32-year-old patients with HBeAg-positive CHB. We then used the model to estimate the lifetime clinical benefits in terms of life years (LYs), quality-adjusted life years (QALYs), and lifetime costs associated with treatment. We evaluated the following two CHB treatment strategies: (1) lamivudine 100 mg monotherapy up to a maximum of 4 years or until patients achieve HBeAg seroconversion, and (2) peginterferon a-2a 180 mg monotherapy for 48 weeks. Although our analysis is based on the 1-year randomized controlled trial by Lau et al. [14] , we estimated longerterm lamivudine seroconversion rates from uncontrolled studies to more closely model clinical practice. The comparative performance of alternative treatment strategies was measured by the incremental cost-effectiveness ratio (ICER), defined as the additional cost of a specific strategy, divided by its additional clinical benefit, compared with the next least expensive strategy. We adopted the perspective of the UK National Health Service (NHS) and used a lifetime timeframe for the analysis [15] . One-way and probabilistic sensitivity analyses were performed to determine how changes in estimated values affect the results. All costs were discounted at a 6% annual rate and outcomes (e.g. QALYs) at 1.5%, in accordance with UK guidelines at the time of this analysis [15] .
Model structure and cohort characteristics
The model consisted of eight health states: HBeAg seroconversion, HBeAg-positive CHB, compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation, postliver transplantation, and death ( Fig. 1 ). Transitions between health states occurred every 12 months. Our model structure was similar to previously published models by Crowley et al. and Pwu and Chan, except that Crowley et al. did not include health states to account for patients receiving a liver transplantation [16] [17] [18] [19] .
The hypothetical cohort of patients was based on the clinical and demographic characteristics of patients of the pivotal clinical trial [14] . The cohort was defined as those with a histological diagnosis of CHB, HBsAg-positive for more than 6 months, and detectable HBV DNA > 500 000 copies/ml. Baseline characteristics of study patients were: mean age 32 years; 78% male; 87% Asian; and 17% with compensated cirrhosis or transition to cirrhosis. The mean baseline ALT was 110.6 U/l [ > 2 Â ULN (upper limit of normal)]. In the model, all patients were assumed eligible for treatment, similar to the patient population in the clinical trials.
In accordance with the clinical trial, all patients in the model were assumed to have CHB, and therefore all model subjects started in the CHB health state. Peginterferon a-2a (40 kDa) patients who sustained seroconversion 6 months after treatment transitioned to the seroconversion state, and received no additional treatment. For lamivudine patients, transition to the seroconversion health state was coupled with one 6-month course of consolidation treatment and no therapy thereafter. Despite the emergence of drug resistance, in clinical practice lamivudine is commonly given beyond 1 year to patients who do not achieve initial HBeAg seroconversion with the goal of achieving viral suppression and additional HBeAg seroconversion. We thus elected to model 3 additional years of lamivudine treatment, despite the lack of randomized controlled clinical trial data for long-term lamivudine effectiveness. Specifically, we assumed that lamivudine patients who did not achieve sustained seroconversion after 48 weeks of treatment were continued on lamivudine for up to 4 years, or until they achieved seroconversion.
In both treatment arms, subsequent treatment relapse (transition from seroconversion state to CHB state) could occur in the first year after treatment. After either treatment was stopped, all patients could experience spontaneous seroconversion or relapse on an annual basis. Patients who had not seroconverted were assumed to progress in a manner similar to the natural course of untreated patients and were therefore at risk for compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation, or death. Patients in the seroconversion health state had a small risk of developing compensated cirrhosis.
As the primary goal of antiviral treatment for HBeAgpositive CHB is to stop viral replication through HBeAg seroconversion, we modeled this as the primary treatment effect. Therefore, we assumed no additional clinical benefit produced by treatment beyond treatmentinduced HBeAg seroconversion. In the model, patients who remained in the seroconversion health state were assumed to have the same life expectancy as healthy individuals.
Finally, in our base case analysis, we were conservative and did not make additional adjustments to account for the problem of lamivudine drug resistance, as the rates of additional seroconversion in the available lamivudine clinical data are not explicit in whether drug resistance is captured within the data. We, however, evaluated the impact of resistance in a scenario analysis.
Transition probabilities
A thorough review of the clinical and health economics literature was conducted to identify studies that reported probabilities of clinical events relevant to the model. These data are listed in Table 1 . The estimates for sustained seroconversion after 48 weeks of treatment were derived from Lau et al. [14] . Specifically, we utilized end of follow-up data, that is, 6 months after cessation of therapy. Estimates of seroconversion rates for lamivudine for years 2-4 were derived from noncontrolled follow-up studies of lamivudine treatment [20] [21] [22] . We assumed there was additional treatment relapse beyond that observed at 6 months after treatment, as has been found in longer-term follow-up studies of lamivudine and interferon. Specifically, in a meta-analysis of patient-level data, van Nunen and colleagues [25, 29] found that, in patients with a baseline ALTof 2-5 ÂULN, an additional 35% of lamivudine patients relapsed beyond 6 months after treatment, compared with 8% of interferon patients. Although peginterferon a-2a (40 kDa) may have less treatment relapse than conventional interferon, we conservatively used data from non-pegylated interferon IFN-a studies (8%) in our analysis. We estimated that additional treatment relapse occurred in 25% rather than 35% of lamivudine-treated patients to account for the potential impact of extended therapy on seroconversion durability [25, 29] . We derived estimates for spontaneous seroconversion and seroreversion from previous HBV cost-effectiveness studies [16, 26] . UK all-cause mortality rates were estimated for patients without disease-attributable mortality risks based upon published UK life tables (www.GAD.org.uk).
Costs and quality of life (utility) values
Weekly drug acquisition costs of d132 and d20 for peginterferon a-2a (40 kDa) 180 mg and lamivudine 100 mg daily, respectively, were taken from the British National Formulary (BNF). Patients were assumed to receive the full course of therapy, although 46% of peginterferon a-2a (40 kDa) patients in the Lau et al. trial [14] received dose reductions.
Health state costs were obtained from the UK's NICE review of hepatitis B treatments in the UK [30] . In the NICE review, health state costs were based on treatment protocols developed with expert advisors, published cost estimates for the progressive stages of liver disease, an observational study in mild hepatitis C in the UK, and a study of the costs of liver transplantation in the UK [30] .
We did not include the cost of monitoring drug side effects or resistance. The costs of treating all common adverse events (AEs) for both treatments were estimated based on the incidence of AEs reported by Lau et al. [14] . On average, reported AEs were relatively mild [only 4 and 2% of patients had one or more serious AEs on peginterferon a-2a (40 kDa) and lamivudine, respectively] and inexpensive to treat. The rates of AEs were significantly higher in the peginterferon a-2a (40 kDa) group than the lamivudine group (P < 0.001); however, most of the side effects associated with peginterferon a-2a (40 kDa) could be treated with analgesics or dose reduction. For example, the most common side effects with peginterferon a-2a (40 kDa) were flu-like symptoms and mild myelosuppression. The incidence of upper respiratory tract infections was similar in both treatment groups. Costs of side effects were estimated from the typical course of treatment for each side effect observed in the trial, based upon expert medical opinion. We then applied the associated drug cost, as listed in the BNF. Owing to the relatively small number of serious side effects and inexpensive treatments, the average costs of treating side effects per patient per year of treatment were d6.48 and d2.04 for peginterferon a-2a (40 kDa) and lamivudine, respectively.
Quality of life (utility) values associated with CHB disease states were based on data obtained from previously published economic evaluations of treatments for hepatitis in which utilities were obtained from an average of the standard gamble and time trade off methods in clinician experts; these utilities were varied ± 20% in sensitivity analyses (Table 2 ) [26, 28] . For those patients who seroconverted, UK population-based agespecific quality of life weights were applied [31] . Utility estimates for the other health states were age-adjusted in an analogous fashion to ensure consistency in the relative values throughout the simulation. Based on published modeling studies [26, 32] , we applied an absolute decrease in utility of 0.05 to peginterferon a-2a (40 kDa) treatment compared with lamivudine to account for symptoms during therapy that may affect quality of life.
Sensitivity and scenario analyses
Sensitivity analyses were performed on each model input to determine the impact of parameter uncertainty on the estimated ICERs. We also conducted a probabilistic sensitivity analysis and generated a cost-effectiveness acceptability curve using Monte Carlo simulation methods, as recommended by the NICE guidance on methods for technology appraisal [15] .
We also evaluated a scenario in which adefovir salvage treatment was used for lamivudine-resistant patients. Annual seroconversion rates and drug costs for lamivudine-treated patients were modified based on the proportion of patients with resistance each year rather than explicitly including a resistance health state. We derived estimates of the incidence of lamivudine resistance (26%/year) from a review of long-term treatment [10] . The increase in the HBeAg seroconversion rate for resistant patients who received adefovir salvage therapy was obtained from a recent randomized controlled trial of adefovir-lamivudine combination therapy vs. lamivudine monotherapy in lamivudine-resistant patients (8 vs. 3% HBeAg seroconversion at end of 1 year of treatment, respectively) [11] . We conservatively assigned only the cost of adefovir (d73.5 per week per BNF) for patients receiving salvage therapy.
Results
Base case analyses
The estimated clinical and economic outcomes of individual treatment strategies following a 48-week course of therapy for peginterferon a-2a (40 kDa) and 4-year treatment with lamivudine are shown in Table 3 . The total discounted cost with peginterferon a-2a (40kDa) was d14 900 per patient vs. d11 800 for lamivudine. Peginterferon a-2a (40 kDa) compared with lamivudine increased life expectancy by 0.60 years and discounted life expectancy and quality-adjusted life expectancy by 0.39 and 0.30 years, respectively. This yielded discounted ICERs of d8000 per life year gained and d10 400 per QALY gained.
Sensitivity analyses
As shown in Fig. 2 , estimated ICERs were most sensitive to variation in the probability of developing compensated cirrhosis from CHB, peginterferon a-2a (40 kDa) seroconversion rate, relapse after lamivudine treatment and the probability of developing compensated cirrhosis from the seroconversion state. The ICER for peginterferon a-2a (40 kDa) compared with lamivudine monotherapy ranged from d8300 to d15 400 per QALY gained despite variation in treatment efficacy, drug cost, the health state transition probabilities, utility values and health state cost estimates. The cost-effectiveness acceptability curve (Fig. 3 ) generated from the probabilistic sensitivity analysis indicated that there was a greater than 95% probability that peginterferon a-2a (40 kDa) was cost-effective compared with lamivudine at the d30 000 per QALY threshold (95% central range of results, d6000-d26 500 per QALY gained). The scenario analysis exploring the impact of adefovir salvage therapy for lamivudine-resistant patients showed that peginterferon a-2a (40 kDa) increased life years by 0.33 and discounted QALYs by 0.14.
Overall costs were higher with peginterferon a-2a (40 kDa) in comparison with lamivudine plus adefovir salvage [d875 more with peginterferon a-2a (40 kDa)], yielding a discounted ICER of d6100 per QALY gained.
Discussion
Using a Markov simulation model and data from clinical trials, we estimated the cost-effectiveness of peginterferon a-2a (40 kDa) compared with lamivudine as first-line treatment for patients with CHB from the perspective of the UK National Health Service. Our findings suggest that use of peginterferon a-2a (40 kDa) is highly likely to be cost-effective, given certain assumptions about disease progression and the efficacy and cost of therapy. The ICERs were most sensitive to variation in the probability of developing compensated cirrhosis from CHB, peginterferon a-2a (40 kDa) seroconversion rate, lamivudine treatment durability, and the probability of developing compensated cirrhosis from seroconversion. However, when these parameters were varied over a range of estimates using one-way and multi-way sensitivity analyses, the ICER did not exceed the d30 000/QALY threshold.
A previous economic study in the UK performed by the Southampton Health Technology Assessment Centre (SHTAC) as part of the recent NICE assessment of Chronic Hepatitis C (CHC) evaluated the costeffectiveness of a variety of treatments using similar Markov modeling techniques [30] . This study concluded that peginterferon a-2a (40 kDa) was a cost-effective first-line treatment strategy for HBeAg-positive CHB in a comparison of multiple treatment strategies including lamivudine, adefovir, and sequential therapies. The increase in discounted costs and QALYs (d3500 and 0.18, respectively) yielded an ICER of d19 200 per QALY £5000 £10000 £15 000 £20 000 £25 000
Results of the probabilistic sensitivity analysis, represented as a costeffectiveness acceptability curve. A decision-makers value for a quality adjusted life year is plotted on the x-axis, and the probability that the intervention is cost-effective across these values is plotted on the y-axis. QALY, quality-adjusted life year.
gained. The most likely reason for the difference in the results is that the NICE analysis used a seroconversion rate of 18% for lamivudine in year 1 (vs. 19% in our study) and assumed an 18% probability of seroconversion thereafter (vs. 10-15% in our study). These differences highlight the challenge of modeling long-term treatment and outcomes in CHB and the need for longer-term controlled trials. Indeed, recent 2-year randomized controlled trial results have shown that the probability of seroconversion in the second year of lamivudine therapy in patients without resistance is approximately 15% [33] . The NICE analysis also assumed the probability of developing compensated cirrhosis during the first year of lamivudine treatment was 2%, compared with 9% at baseline and for other treatments. This estimate was based on limited data, and may reflect a combination of both HBeAg seroconversion and viral suppression [34] . HBV DNA viral load has been correlated with the incidence of cirrhosis in untreated patients, although there are no conclusive studies confirming this effect in treated patients [35] . In a scenario analysis in which the effect of adefovir salvage therapy for lamivudine-resistant patients was evaluated, we found that discounted life expectancy was increased compared with lamivudine monotherapy, but peginterferon a-2a (40 kDa) therapy still resulted in higher QALYs and was cost-effective. The ICER for peginterferon a-2a (40 kDa) vs. lamivudine plus adefovir salvage (d6100/ QALY) is lower than the ICER for peginterferon a-2a (40 kDa) vs. lamivudine monotherapy (d14 700/QALY) because the incremental benefit of salvage therapy is achieved at a relatively higher price (less efficiently). Our analysis of salvage therapy differs from previous analyses because we were able to utilize recent data from a randomized control trial, which showed an end-oftreatment seroconversion rate of 8% for combination salvage therapy [11] .
There are several limitations of our analysis worth noting. First, as with almost all long-term modeling studies, there are inherent uncertainties in projecting long-term outcomes. We evaluated these uncertainties using probabilistic sensitivity analyses, and found that the results held over a wide range of assumptions. With regard to specific parameters, we assumed that patients in the CHB health state followed the same clinical course and rates of progression as untreated patients, that is, they followed the natural history of CHB disease. This assumption, however, is consistent with several published costeffectiveness analyses of treatment for both CHB and CHC in which non-responders and untreated patients progress identically [16, 36, 37] . We did not include HBsAg seroconversion in the analysis. Although peginterferon may result in higher rates of HBsAg seroconversion compared with lamivudine, we chose to be conservative. Another limitation of our study is that we did not model sequential therapy other than adefovir salvage, nor did we model combination therapy (i.e. adefovir plus lamivudine), although patients may be treated with these strategies in clinical practice. Currently, no clinical trial data are available indicating that treatment response in sequential or combination therapy is the same as in first-line peginterferon a-2a (40 kDa) treatment [e.g. an antiviral given after peginterferon a-2a (40 kDa) treatment]. Lastly, it should be noted that cost-effectiveness information is one of several important factors considered by decision-makers, such as budget impact and equity.
There has been much discussion surrounding a possible cost-effectiveness threshold in the UK. NICE currently states that 'above an ICER of d30 000/QALY the case for supporting the technology on these factors has to be increasingly strong' [15] . On the basis of this guidance, our results thus suggest that 48 weeks of treatment with peginterferon a-2a (40 kDa) compared with 4 years of treatment with lamivudine offers both life expectancy and QALY benefits at a favorable cost-effectiveness ratio in CHB patients who are HBeAg-positive.
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